ABSTRACT
INTRODUCTION
With the recent rapid aging of the population, we are seeing an increasing number of elderly patients with asthma. The incidence of asthma has been reported to increase with age. 1 As previously reported, 2 some elderly patients have early-onset asthma that is severe and persists for a prolonged period , whereas other elderly patients have late-onset asthma that lasts for a short period. We speculated that there may be some differences in the clinical features between the two groups. In other words, since the duration of asthma is shorter in the late-onset group, better response to treatment was expected . In the present study, we compared the characteristics of late-onset asthma with those of early-onset asthma in elderly patients. We also examined whether there was any difference in efficacy of inhaled corticosteroid treatment between the two groups under the same therapeutic strategy.
METHODS
Of 328 asthma patients admitted to our hospital and managed under a clinical pathway of bronchial asthma from 1998 through 2004, 109 patients aged 60 years or older were included in this study . All patients met the American Thoracic Society criteria for asthma . None of the patients were instructed until hospitalization to regularly take inhaled corticosteroids (ICS) at their appropriate dosage . The clinical F i g . 1 T h e r e l a t i o n s h i p b e t we e n s e r u m I g E l e v e l s a n d a g e o f o n s e t i n a l l e l d e r l y a s t h ma p a t i e n t s a g e d 6 0 o r o l d e r . T h e r e wa s a s i g n i f i c a n t n e g a t i v e c o r r e l a t i o n b e t we e n t h e t wo v a r i a b l e s ( r ＝− 0 . 
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me a n ± S . E . pathway of patients who were admitted with moderate or severe asthma exacerbations (defined by the 2002 GINA Guidelines ) consisted of simultaneous treatment of asthma exacerbations, thorough examination, and education for an eight-day period. At the time of discharge, improvement in FEV1.0 by 20% or more as compared with that at admission, and chest CT showing no low attenuation areas were confirmed.
After completion of the clinical pathway during the hospital stay, the patients received step-down therapy with ICS (fluticasone propionate dry powder) on an outpatient basis. During the hospital stay, the patients were given careful instructions on how to inhale corticosteroids . The dose of fluticasone was decreased stepwise every 4 months from 800 to 600, 400, 300, 200, and 100 μg! day after discharge if the asthma condition remained ' totally controlled' or ' well controlled'. 3 In the case of the occurrence of an asthma exacerbation during dose reduction , systemic steroids could be used and fluticasone was increased to the previous dose. As concomitant therapy, theophylline and! or pranlukast and! or salmeterol were used until the dose of fluticasone reached 200 μg! day. Salbutamol was used as a reliever. Those whose asthma was poorly controlled with these treatments received oral methylprednisolone. Asthma severity was rated according to the 2002 GINA Guidelines by three allergology specialists. Severity was scored with 1 to 4 points given to steps 1 to 4, respectively , and the scores were compared.
RESULTS
Of 328 patients with bronchial asthma who successfully completed the clinical pathway , 109 patients (33%) were aged 60 or older. Of these, 51 (47%) had late-onset asthma (onset at age 60 or older) and 58 (53%) had early-onset asthma (onset before age 60); no significant differences were found between the groups in terms of gender ratio and the number of ' never smokers' ( Table 1 ) . The duration of asthma was markedly shorter in the early-onset group (3.1 ± 0.4 years ) than in the late-onset group ( 23.8 ± 2.3 years). Serum IgE levels were significantly lower in the late-onset group (242 ± 45 IU! mL) than in the early-onset group (569 ± 105 IU! mL). With regard to pulmonary function , there were no differences in FEV1.0! VCpred or RV! TLC (% pred) between the two groups. Among patients aged 65 or older, there was no difference in mean age (72.9 ± 6.2 vs. 71.0 ± 5.6, n. s.) but serum IgE was significantly lower in patients in the late-onset group (199.4 ± 44.7 vs. 553.6 ± 173.8, p < 0.05). Statistical analysis was performed using the Mann-Whitney U test.
The relationship between serum IgE levels and age of onset in all patients aged 60 or older is shown in Figure 1 . There was a significant negative correlation between the two variables (r = −0.415, p < 0.0001 by Pearson's correlation and p = 0.0012 by Spearman's correlation). The correlation coefficient between the logarithmic value of IgE and age of onset was r = −0.339 (p = 0.0006 by Pearson's correlation and p = 0.0012 by Spearman's correlation).
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Step of severity of asthma *** *** *** * ** * Figure 2 shows the positive rates of specific IgE antibodies to common allergens in Japan. The positive rates of specific IgE antibodies to Japanese Cedar pollen and house dust mite (D.f), unlike other allergens, were significantly lower in the late-onset group ( χ 2 test). Table 2 shows the outcomes after step-down therapy . Asthma severity was expressed in numbers , based on the severity ratings, steps 1 to 4. Severity at the time of admission was significantly lower in the late-onset group. The same tendency was also seen at 1 and 2 years after the start of treatment. Statistical analysis was performed using the Mann-Whitney U test. The dropout ratio was significantly greater in the late-onset group (χ 2 test). A dropout case is a case in which asthma severity cannot be judged accurately for a year due to the patient's failure to regularly visit the hospital. Thirty-four dropout patients stopped visiting the hospital regularly because of marked decreases in the severity of their asthma symptoms . Some of these continued being seen by other physicians for treatment of other diseases. In 8 dropout patients the reason was unknown. Figure 3 shows the course of asthma severity in patients who continued to receive treatment for 2 years. In the late-onset group, severity showed a significant decrease at 1 year (p < 0.01), and a further decrease at 2 years (p < 0.0001). Meanwhile, there was no significant improvement at 1 year in the early-onset group, but a significant decrease was seen finally at 2 years (p < 0.0001 ) ( Fisher's PLSD ) . Severity was lower in the late-onset group than in the early-onset group (p < 0.0001, repeated measures ANOVA).
DISCUSSION
In this study , we found an inverse correlation between IgE levels and age of onset in elderly asthma patients as a whole. Moreover, IgE levels were lower in the late-onset group. This may be explained by less sensitivity to common allergens such as Japanese Cedar pollen and house dust mite as shown in Figure 2 . As previously reported, 4 IgE mediation was thought to be less frequent in the late-onset group . Other mechanisms than IgE mediation may be important for stimulating Th2 cells in elderly onset asthma.
We have been applying a step-down therapy with ICS as early as possible in elderly asthma patients as the basic strategy, as well as in younger asthma patients . As in the GOAL study , 3 our treatment has been aimed at achieving the guideline-defined total control of asthma. As a result, response to such treatment in the late-onset group was better than that in the early-onset group; severity at onset was lower , and more rapid improvement in the severity was shown 1 year after the start of treatment. The primary reason for this is that the duration of asthma from onset is shorter and intervention with ICS is earlier .
Since airway wall remodeling is induced by chronic airway inflammation, it is important to start ICS therapy as soon as possible. 5, 6 Early and long term intervention with ICS can prevent airway remodeling. 7 As in other age groups , early intervention with ICS seems to play a key role also in elderly asthma patients.
In this study we applied a new analysis comparing the 'severity steps' with the results of longstanding step-down therapy because the guidelines aimed to achieve the step-down of severity if possible . The lung function or symptom score alone were not different between the two groups, because the classification of severity was based on both ' symptoms and
